What Happened to Your Peptide? The 2026 FDA Reclassification Explained

If you've been following peptide therapy for any length of time, the past three years have felt like regulatory whiplash. In September 2023, the FDA placed 19 widely used peptides on its Category 2 restricted list, effectively banning licensed compounding pharmacies from preparing them. By February 2026, HHS Secretary Robert F. Kennedy Jr. was announcing that most of those restrictions would be reversed. And on April 15, 2026, the FDA formally began removing 12 of those peptides from the restricted list.

For women who rely on peptides for everything from PCOS management to gut healing to perimenopause support, the confusion has been real. This article breaks down exactly what happened, where things stand today, and what's coming next — including the critical July 23–24 PCAC meeting that will determine the future of peptide compounding in the United States.

The Timeline: How We Got Here

September 2023: The Category 2 Designation

Under the Drug Quality and Security Act (DQSA), the FDA maintains a list of bulk drug substances that compounding pharmacies can use to prepare patient-specific medications under Section 503A. In September 2023, the FDA placed 19 peptides into Category 2 — a designation reserved for substances the agency determined raised "significant safety concerns."

The effect was immediate. Compounding pharmacies that had been producing BPC-157, Thymosin Alpha-1, TB-500, and other peptides for patients with active prescriptions stopped overnight. Practitioners scrambled for alternatives, and patients were left without therapies they'd been using — often successfully — under physician supervision.

The Category 2 designation didn't technically "ban" peptides. It prohibited licensed compounding pharmacies from using these substances, which effectively removed them from the regulated healthcare system. The unintended consequence? Demand shifted to unregulated online vendors, gray-market suppliers, and international sources with no quality oversight.

February 27, 2026: The Kennedy Announcement

During an appearance on The Joe Rogan Experience, HHS Secretary Kennedy stated that the FDA was expected to take action "within a couple of weeks" to reverse most of the Category 2 restrictions. He described himself as a "big fan" of peptides and criticized what he characterized as the prior administration's mishandling of peptide policy.

Kennedy's core argument was pragmatic: the restrictions didn't stop people from using peptides. They just pushed demand underground, into channels without quality controls, purity testing, or medical supervision. Restoring regulated access through licensed compounding pharmacies, he argued, was safer than maintaining a prohibition that wasn't working.

April 15, 2026: The Formal FDA Action

The FDA officially updated its 503A Bulks List, announcing the removal of 12 peptides from Category 2 within seven calendar days (effective April 22, 2026). The reason given: the companies that originally nominated these peptides for Category 2 withdrew their nominations.

On the same day, the FDA published a Federal Register Notice scheduling the Pharmacy Compounding Advisory Committee (PCAC) for July 23–24, 2026, to evaluate whether these peptides should be formally added to the 503A bulks list.

The 12 Peptides Removed from Category 2

What "Removed from Category 2" Actually Means

This is the part that trips people up. Removal from Category 2 does not mean these peptides are now legal to compound. It means they no longer carry the "significant safety risks" designation. But they haven't been placed on Category 1 either — they're in regulatory limbo.

For a peptide to be legally compoundable by 503A pharmacies, it needs to either be on the Category 1 list (where substances can be compounded while under FDA review) or be formally added to the 503A bulks list through the PCAC process.

The PCAC meetings — July 2026 for the first seven peptides, February 2027 for the remaining five — are where the actual decisions get made. The committee will review safety data, adverse event reports, and clinical utility for each peptide individually and make recommendations to the FDA.

Why This Matters for Women

Several of the peptides affected by this regulatory shift are particularly relevant to women's health. BPC-157, which has the strongest research for gut healing (IBS is 2x more common in women), was the most widely compounded peptide before the 2023 restrictions. KPV, which targets inflammatory and autoimmune conditions (80% of autoimmune patients are female), was only available through research suppliers during the restriction period.

MOTS-C, which improves insulin sensitivity through AMPK activation, is being studied specifically for PCOS-related metabolic dysfunction. And DSIP, one of the few peptide options for perimenopause insomnia, has been inaccessible through regulated channels since 2023.

The restriction period pushed many women toward unregulated sources — a particular concern for peptides that require proper reconstitution, sterile technique, and dosing guidance. The restoration of regulated access, if the PCAC process goes favorably, would bring these therapies back under physician supervision with quality-controlled compounding.

What's Still Restricted

Seven peptides from the original 19 remain on the Category 2 list as of May 2026 and were not part of the April removal. These include several peptides commonly used in women's health protocols:

• Thymosin Alpha-1 — immune modulation, used for autoimmune and chronic infection support
• CJC-1295 and Ipamorelin — growth hormone secretagogues, popular for sleep, body composition, and perimenopause support
• AOD-9604 — fat metabolism peptide studied for menopause-related weight gain
• Selank — anxiolytic peptide used for mood and anxiety (2x more prevalent in women)
• Kisspeptin-10 — HPG axis regulator, critical research target for PCOS and fertility
• GHRP-2, GHRP-6, and MK-677 (Ibutamoren) — growth hormone secretagogues with stronger safety concern profiles

For women relying on Selank for anxiety, CJC-1295/Ipamorelin for sleep and body composition, or Kisspeptin-10 for hormonal regulation, these remain unavailable through licensed compounding pharmacies. Research-grade suppliers continue to carry these peptides, but without the quality assurance of regulated compounding.

The Political Context

It's worth understanding the political dynamics that made this reclassification possible. The current administration has signaled broader support for peptide access than its predecessor. Secretary Kennedy has been publicly critical of the 2023 restrictions and has positioned the reversal as both a safety measure (reducing gray-market dependency) and a patient-access issue.

However, the PCAC process is not a guaranteed outcome. Under the Biden administration, several peptides that went through the PCAC process received recommendations against inclusion on the 503A bulks list. The current environment is different — the PCAC has significant vacancies that could be filled before the July meeting, and the administration's posture is more favorable — but the regulatory process itself is designed to be evidence-based, not politically driven.

Public engagement matters. Written comments submitted by July 9, 2026, will be provided directly to the PCAC committee. If you've used peptides under physician supervision and have a story to tell, the public comment period is the mechanism for making your voice heard.

What to Do Right Now

Frequently Asked Questions

Related Reading